ESTIMACIÓN DE LA SEMIVIDA DE ELIMINACIÓN Y RECUPERACIÓN IN VIVO DEL FACTOR VON WILLEBRANS CONTENIDO EN FANHDI (FACTOR ANTIHEMOFÍLICO HUMANO DOBLEMENTE INACTIVADO) EN PACIENTES CON ENFERMEDAD DE VON WILLEBRAND

Dades bàsiques

Protocol:
IG001
EURDRACT:
NCT:
Centre:
Any inici:
Any de finalització:
ENSAYO CLÍNICO

Documents

  • No hi ha documents

Participants

Grups d'Investigació

Finançadors - Promotors

INSTITUTO GRIFOLS SA

Resultats de l'Assaig Clínic


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Efficacy and safety evaluation of Fanhdi ® , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.

Jimenez-Yuste, Victor; (...); Paez, Antonio

Letter. 10.1111/hae.14453. 2022

  • Open Access.

Emicizumab-induced photosensitivity.

Asensi Canto, Pedro; (...); Haya Guaita, Saturnino

Article. 10.1055/s-0042-1749092. 2022


Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions

Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta

Meeting Abstract. 2024


Management of acquired hemophilia A: results from the Spanish registry.

Mingot-Castellano ME; (...); Marco P

Article. 10.1182/bloodadvances.2021004626. 2021

  • Open Access.

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

  • Open Access.

Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.

Megias-Vericat, J. E.; (...); Poveda Andres, J. L.

Article. 10.1016/j.thromres.2022.06.001. 2022


Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.

Megias-Vericata, J. E.; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2023.11.023. 2023


Compartir el projecte